Literature DB >> 28504663

A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS.

R J van de Peppel1, P A von dem Borne2, S le Cessie3, M G J de Boer1.   

Abstract

Invasive aspergillosis (IA) has been reported to yield high mortality rates. Patients with an unfavourable prognostic haematological disease not only have a higher probability of developing IA but are also more likely to die due to causes directly related to the underlying disease. This complexity of risk mechanisms confounds the causal interpretation of IA occurrence and mortality. Full consideration of the changing patient characteristics over time is necessary to obtain reliable estimates of the correlation of IA with mortality. We studied the effect of IA on mortality in 167 consecutive patients starting with remission-induction therapy for AML or of whom most patients continued to haematopoietic stem cell transplantation (HSCT). No standard antifungal prophylaxis was administered in the period before HSCT. Survival analyses were performed to determine risk estimates of IA for different phases of treatment before and after HSCT. Time-dependent adjustment for confounding variables was performed using Cox proportional hazards models. In 55 of 167 enroled patients, IA was diagnosed. Before HSCT, adjusted hazard ratios and 95% confidence intervals on mortality after the diagnosis of IA were 3.5 (1.7-7.5), 2.0 (0.69-5.9), 2.3 (0.79-6.8) and 0.80 (0.49-1.4) within 30 days, between 30 and 60 days, between 60 and 90 days or more than 90 days, respectively. A similar pattern was observed after HSCT. The occurrence of IA did not significantly influence the decision to follow through with HSCT. The results provide new insights in short- and long-term survival of patients diagnosed with IA. A significantly increased mortality risk was only observed in the first month after diagnosis of IA. No unfavourable association with mortality was observed in the later course of treatment. The occurrence of IA did not affect the probability of attaining HSCT in our population.

Entities:  

Mesh:

Year:  2017        PMID: 28504663     DOI: 10.1038/bmt.2017.71

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  30 in total

Review 1.  Clinical risk factors for invasive aspergillosis.

Authors:  John W Baddley
Journal:  Med Mycol       Date:  2010-08-18       Impact factor: 4.076

2.  Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies.

Authors:  Jutta Auberger; Cornelia Lass-Flörl; Hanno Ulmer; Elisabeth Nogler-Semenitz; Johannes Clausen; Eberhard Gunsilius; Hermann Einsele; Günther Gastl; David Nachbaur
Journal:  Int J Hematol       Date:  2008-11-05       Impact factor: 2.490

3.  Persistent poor long-term prognosis of allogeneic hematopoietic stem cell transplant recipients surviving invasive aspergillosis.

Authors:  Géraldine Salmeron; Raphaël Porcher; Anne Bergeron; Marie Robin; Régis Peffault de Latour; Christèle Ferry; Vanderson Rocha; Anna Petropoulou; Aliénor Xhaard; Claire Lacroix; Annie Sulahian; Gérard Socié; Patricia Ribaud
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

Review 4.  Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection.

Authors:  I Mirkov; S Stosic-Grujicic; M Kataranovski
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 5.  Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality.

Authors:  Ellen Meijer; Jan J Cornelissen
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

6.  Causal directed acyclic graphs and the direction of unmeasured confounding bias.

Authors:  Tyler J VanderWeele; Miguel A Hernán; James M Robins
Journal:  Epidemiology       Date:  2008-09       Impact factor: 4.822

7.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).

Authors:  Bernard Tawfik; Timothy S Pardee; Scott Isom; Sarunas Sliesoraitis; Allison Winter; Julia Lawrence; Bayard L Powell; Heidi D Klepin
Journal:  J Geriatr Oncol       Date:  2015-10-30       Impact factor: 3.599

9.  Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients.

Authors:  M Mikulska; A M Raiola; B Bruno; E Furfaro; M T Van Lint; S Bregante; A Ibatici; V Del Bono; A Bacigalupo; C Viscoli
Journal:  Bone Marrow Transplant       Date:  2009-03-23       Impact factor: 5.483

10.  Agent-based modeling approach of immune defense against spores of opportunistic human pathogenic fungi.

Authors:  Christian Tokarski; Sabine Hummert; Franziska Mech; Marc Thilo Figge; Sebastian Germerodt; Anja Schroeter; Stefan Schuster
Journal:  Front Microbiol       Date:  2012-04-26       Impact factor: 5.640

View more
  2 in total

Review 1.  Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species.

Authors:  Anna Dudakova; Birgit Spiess; Marut Tangwattanachuleeporn; Christoph Sasse; Dieter Buchheidt; Michael Weig; Uwe Groß; Oliver Bader
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

2.  Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data.

Authors:  Léa Bolcato; Charles Khouri; Anette Veringa; Jan Willem C Alffenaar; Takahiro Yamada; Takafumi Naito; Fabien Lamoureux; Xavier Fonrose; Françoise Stanke-Labesque; Elodie Gautier-Veyret
Journal:  J Clin Med       Date:  2021-05-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.